SG153666A1 - Treatment of hepatitis b virus infection with human monoclonal antibodies - Google Patents
Treatment of hepatitis b virus infection with human monoclonal antibodiesInfo
- Publication number
- SG153666A1 SG153666A1 SG200702600-8A SG2007026008A SG153666A1 SG 153666 A1 SG153666 A1 SG 153666A1 SG 2007026008 A SG2007026008 A SG 2007026008A SG 153666 A1 SG153666 A1 SG 153666A1
- Authority
- SG
- Singapore
- Prior art keywords
- hepatitis
- treatment
- monoclonal antibodies
- virus infection
- human monoclonal
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Disclosed is a pharmaceutical composition for the treatment or prevention of hepatitis B virus infection, comprising a 1:3 mixture of two fully human anti HBsAg monoclonal antibodies 19.79 and 17.1.41. Also disclosed are preferred modes of administration. The pharmaceutical composition can be given as a monotherapy or in combination with other anti viral agents.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG200702600-8A SG153666A1 (en) | 2001-10-04 | 2001-10-04 | Treatment of hepatitis b virus infection with human monoclonal antibodies |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG200702600-8A SG153666A1 (en) | 2001-10-04 | 2001-10-04 | Treatment of hepatitis b virus infection with human monoclonal antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG153666A1 true SG153666A1 (en) | 2009-07-29 |
Family
ID=40901912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200702600-8A SG153666A1 (en) | 2001-10-04 | 2001-10-04 | Treatment of hepatitis b virus infection with human monoclonal antibodies |
Country Status (1)
Country | Link |
---|---|
SG (1) | SG153666A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997047654A1 (en) * | 1996-06-11 | 1997-12-18 | Yeda Research And Development Co. Ltd. | Human monoclonal antibodies to the hepatitis b surface antigen |
WO1997047653A1 (en) * | 1996-06-11 | 1997-12-18 | Xtl Biopharmaceuticals Limited | Human monoclonal antibody against hepatitis b virus surface antigen (hbvsag) |
-
2001
- 2001-10-04 SG SG200702600-8A patent/SG153666A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997047654A1 (en) * | 1996-06-11 | 1997-12-18 | Yeda Research And Development Co. Ltd. | Human monoclonal antibodies to the hepatitis b surface antigen |
WO1997047653A1 (en) * | 1996-06-11 | 1997-12-18 | Xtl Biopharmaceuticals Limited | Human monoclonal antibody against hepatitis b virus surface antigen (hbvsag) |
Non-Patent Citations (2)
Title |
---|
HUMAN MONOCLONAL ANTIBO * |
PRECLINICAL EVALUATION OF TWO HUMAN ANTI-HEPATITIS B VIRUS (HBV) MONOCLONAL ANTIBODIES IN THE HBV- TRIMERA MOUSE MODEL AND IN HBV CHRONIC CARRIER CHIM * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP1771A (en) | 3'-Prodrugs of 2'-deoxy-?-L-nucleosides. | |
EE05442B1 (en) | A low dose entecavir pharmaceutical composition for the treatment of hepatitis B virus infection and a method for its preparation | |
BR0111195A (en) | Use of b-1,2'-deoxy-nucleosides in the treatment of hepatitis delta virus infection | |
TW200730537A (en) | Methods and compositions for treating hepatitis C virus | |
HK1068538A1 (en) | Antiviral compounds | |
WO2002032414A3 (en) | Ribavirin-pegylated interferon alfa hcv combination therapy | |
AU2002219881A1 (en) | Methods and compositions for the treatment of human immunodeficiency virus infection | |
MD990258A (en) | Method of treatment of the acute viral hepatitis B | |
HK1041215A1 (en) | Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection. | |
IL161138A0 (en) | Treatment of hepatitis b virus infection with human monoclonal antibodies | |
SG153666A1 (en) | Treatment of hepatitis b virus infection with human monoclonal antibodies | |
WO2005016288A3 (en) | Methods and compositions for treatment of viral diseases | |
IL151033A0 (en) | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use | |
WO2004006848A3 (en) | Combination therapies with ftc for the treatment of hepatitis b virus infection | |
DE69706657D1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING NATURAL HUMAN ALPHA INTERFERON | |
WO2004067024A3 (en) | Hcv combination therapy | |
WO2003030613A3 (en) | Methods of treating liver fibrosis and hepatitis c virus infection | |
AU2001270226A1 (en) | Tolerance and chronic hepatitis c virus | |
TR200000728T2 (en) | The use of IFN-alpha and amantadine in the treatment of chronic hepatitis C. | |
HK1039935A1 (en) | Use of (1r, 4s)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol in hbv | |
WO2003006017A3 (en) | Use of certain castanospermine esters in the treatment of influenza virus infections | |
AU8716001A (en) | Treatment of hepatitis c with thymosin and pegylated interferon |